Rockefeller Capital Management
CODX

Rockefeller Capital Management’s Co-Diagnostics CODX Stock Holding History

Rockefeller Capital Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13
Closed -$1K – 2338
2022
Q4 		$1K Hold
13
– – ﹤0.01% 3657
2022
Q3 		$1K Hold
13
– – ﹤0.01% 3686
2022
Q2 		$2K Buy
+13
New +$1.98K ﹤0.01% 3759
2020
Q3 		– Sell
-167
Closed -$97K – 2606
2020
Q2 		$97K Buy
+167
New +$76.2K ﹤0.01% 1178

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Rockefeller Capital Management's CODX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Co-Diagnostics (CODX) in Q1 2023, closing a stake of 13 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in CODX in Q2 2020 and held it in 4 quarters. The position peaked at $97K in Q2 2020. 51 funds tracked by Wall St. Rank hold CODX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Co-Diagnostics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 13 Co-Diagnostics shares in Q1 2023, an estimated $1K.
  • Rockefeller Capital Management first reported a position in Co-Diagnostics in Q2 2020 and held it in 4 quarters.
  • Rockefeller Capital Management's Co-Diagnostics position peaked at $97K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.